Učitavanje...
Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy
INTRODUCTION: Since the identification of the dystrophin gene in 1986, a cure for Duchenne muscular dystrophy (DMD) has yet to be discovered. Presently, there are a number of genetic-based therapies in development aimed at restoration and/or repair of the primary defect. However, growing understandi...
Spremljeno u:
| Izdano u: | Expert Opin Orphan Drugs |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5487007/ https://ncbi.nlm.nih.gov/pubmed/28670506 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21678707.2016.1240613 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|